Related Experiment Video
Updated: Jun 25, 2025
Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
Published on: October 4, 2021
Combinatory Nanovesicle with siRNA-Loaded Extracellular Vesicle and IGF-1 for Osteoarthritis Treatments
Jun Yong Kim1,2,3, Seung Yeon Lee1, Seung-Gyu Cha1
1Department of Biomedical Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea.
Abstract:
Extracellular vesicles (EVs) have been found to have the characteristics of their parent cells. Based on the characteristics of these EVs, various studies on disease treatment using mesenchymal stem cell (MSC)-derived EVs with regenerative activity have been actively conducted. The therapeutic nature of MSC-derived EVs has been shown in several studies, but in recent years, there have been many efforts to functionalize EVs to give them more potent therapeutic effects. Strategies for functionalizing EVs include endogenous and exogenous methods. In this study, human umbilical cord MSC (UCMSC)-derived EVs were selected for optimum OA treatments with expectation via bioinformatics analysis based on antibody array. And we created a novel nanovesicle system called the IGF-si-EV, which has the properties of both cartilage regeneration and long-term retention in the lesion site, attaching positively charged insulin-like growth factor-1 (IGF-1) to the surface of the UCMSC-derived Evs carrying siRNA, which inhibits MMP13. The downregulation of inflammation-related cytokine (MMP13, NF-kB, and IL-6) and the upregulation of cartilage-regeneration-related factors (Col2, Acan) were achieved with IGF-si-EV. Moreover, the ability of IGF-si-EV to remain in the lesion site for a long time has been proven through an ex vivo system. Collectively, the final constructed IGF-si-EV can be proposed as an effective OA treatment through its successful MMP13 inhibition, chondroprotective effect, and cartilage adhesion ability. We also believe that this EV-based nanoparticle-manufacturing technology can be applied as a platform technology for various diseases.
Insights
Researchers developed IGF-si-EVs, a novel nanovesicle for osteoarthritis (OA) treatment. These engineered extracellular vesicles (EVs) promote cartilage regeneration and reduce inflammation, offering a promising therapeutic approach for OA.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Nanotechnology
Background:
- Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) show therapeutic potential for diseases.
- Functionalizing EVs enhances their therapeutic efficacy, with both endogenous and exogenous methods available.
- Osteoarthritis (OA) treatment requires strategies that promote cartilage regeneration and reduce inflammation.
Purpose of the Study:
- To develop a novel, functionalized nanovesicle for optimal osteoarthritis (OA) treatment.
- To create a system combining cartilage regeneration and long-term retention at the lesion site.
- To investigate the therapeutic effects of engineered EVs on inflammation and cartilage repair markers.
Main Methods:
- Human umbilical cord MSC (UCMSC)-derived EVs were selected via bioinformatics analysis.
- A novel nanovesicle, IGF-si-EV, was engineered by attaching insulin-like growth factor-1 (IGF-1) to UCMSC-EVs carrying MMP13-inhibiting siRNA.
- An ex vivo system was used to evaluate the retention ability of IGF-si-EV in lesion sites.
Main Results:
- IGF-si-EV demonstrated downregulation of inflammation markers (MMP13, NF-kB, IL-6) and upregulation of cartilage regeneration markers (Col2, Acan).
- The engineered EVs showed prolonged retention in the lesion site, confirmed by an ex vivo system.
- The study successfully constructed IGF-si-EV with MMP13 inhibition, chondroprotective effects, and cartilage adhesion properties.
Conclusions:
- The engineered IGF-si-EV represents an effective treatment strategy for osteoarthritis (OA).
- This EV-based nanoparticle technology shows potential as a platform for treating various diseases.
- The developed nanovesicle system offers a dual benefit of cartilage regeneration and sustained presence at the target site.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi